Natalie Goedeker, CPNP, on Supporting Gene Therapy’s Ascendance in Muscular Dystrophies


The nurse practitioner from Washington University in St. Louis discussed the practical considerations in gene therapy track she chaired at the 2023 MDA Conference.

"Duchenne muscular dystrophy was denied being added to the recommended newborn screening panel. ...the community has to focus on getting data [in this disease] in the coming years. Probably it will require some sort of clinical trial, but we definitely need data in young children showing that it makes a difference, treating them that their diagnosis from birth will make a difference versus a symptomatic diagnosis in outcomes once we do have a good treatment.”

One track, chaired by Natalie Goedeker, CPNP, pediatric neurology, at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19-22, in Dallas, Texas was the Practical Considerations in Gene Therapy Track that discussed unmet research, education, and infrastructure needs that must be addressed across rare dystrophies such as spinal muscular atrophy and Duchenne muscular dystrophy (DMD).

CGTLive spoke with Goedeker to learn more about the conversations that arose during the practical considerations in gene therapy track. She discussed the importance of having rare diseases like DMD on newborn screening panels and data that will need to come out in the near future to support that implementation. She also touched on positive patient and physician perspectives on accelerated approval shared during one of the sessions on the track at the conference.

Read more coverage of the 2023 MDA Conference here.

Practical Considerations in Gene Therapy Track. Presented at: 2023 MDA Conference, March 19-22; Dallas, Texas.
Related Videos
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Related Content
© 2024 MJH Life Sciences

All rights reserved.